Search Results
Jun 30, 2025, 10:06 ET AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
AvenCell's unique and proprietary allogeneic technology is differentiated from numerous previous cell engineering approaches by applying multiple gene editing steps that ensure a patient's immune system (both innate and adaptive components) is left with no ability to reject the donor cells. Importantly,
More news about: AvenCell Therapeutics, Inc.
Jun 30, 2025, 10:05 ET A new "link" to triple-negative breast cancer
Genome Atlas, a database of over 11,000 cancer patients. The data suggested expression of LINC01235 correlated with that of the breast cancer gene NFIB, already linked to TNBC. Still, "very little" was known about NFIB and next to nothing about LINC01235, Spector says.
More news about: Cold Spring Harbor Laboratory
Jun 30, 2025, 10:00 ET DUBRETON CALLS FOR MANDATORY LABELING OF GENE-EDITED PORK IN NORTH AMERICA
Enforce mandatory labeling of all gene-edited pork products, domestic and imported.Establish a distinct regulatory framework that clearly separates gene-edited pork from conventional and organic meat products."Failing to label gene-edited pork is a direct threat to consumer
More news about: duBreton
Jun 30, 2025, 09:00 ET Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA®
Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate
More news about: Sumitomo Pharma America
Jun 30, 2025, 08:35 ET TriStruX Appoints Tom Prestwood as Chief Executive Officer to Lead Next Phase of Strategic Growth
Gene Callahan, who served as Interim CEO. Callahan will continue to support TriStruX as a strategic advisor and active member of the company's Board of Managers. "Tom's appointment is a defining moment for TriStruX," said Gene Callahan.
More news about: TriStruX LLC
Jun 30, 2025, 08:34 ET Pusan National University Scientists Uncover Gene Mutation Tied to Poor Outcomes in Transplant Patients
May 26, 2025. Giving further insight into their work, Dr. Kim explains, "We discovered a specific genetic variation in a gene called FCGBP that is strongly linked to bronchiolitis obliterans syndrome and poor outcomes following lung transplantation. By using genetic
More news about: Pusan National University
Jun 30, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
with neurofibromatosis type 1, referred to as NF1. They develop from the cells of the peripheral nerve sheath. One in 3,000 people can carry NF1 gene alternations and are predisposed to tumor formation, which can occur anywhere in the body. MPNSTs are most commonly found in the extremities and trunk.
More news about: Intensity Therapeutics Inc.
Jun 30, 2025, 08:00 ET Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. FGFR3 is a frequently altered gene in IR NMIBC, with ~70% of low-grade IR NMIBC showing activating mutations. "Our goal is to develop TYRA-300 as the first once-daily oral treatment
More news about: Tyra Biosciences
Jun 30, 2025, 04:21 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Ltd
Jun 30, 2025, 04:10 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Ltd
Jun 30, 2025, 02:17 ET Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Jun 30, 2025, 02:15 ET Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Jun 30, 2025, 02:00 ET Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered
More news about: Klotho Neurosciences, Inc.
Jun 30, 2025, 02:00 ET Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered
More news about: Klotho Neurosciences, Inc.
Jun 27, 2025, 17:59 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 27, 2025, 11:34 ET Indigo Sky Casino & Resort Celebrates Grand Opening of Rock & Brews Restaurant & Concert Bar
Gene Simmons, Indigo Sky's General Manager Melanie Heskett, and Eastern Shawnee Tribe of Oklahoma's Chief Glenna Wallace. The party continued into the evening with a free live show by the Gene Simmons
More news about: Rock & Brews Restaurants
Jun 27, 2025, 10:30 ET Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™
Germany) Bayer AG plays a key role in the ophthalmology drugs market by marketing Eylea and investing in advanced therapies such as cell and gene therapy. The company has partnered with BlueRock Therapeutics (its wholly owned subsidiary) to drive innovation in the field. In February
More news about: MarketsandMarkets
Jun 27, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jun 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jun 27, 2025, 07:00 ET UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
visual, and sleep impairments as major features.1 It is caused by pathogenic variants in the cyclin dependent kinase-like 5 (CDKL5) gene located on the X chromosome. It is estimated that CDD affects approximately 1 in 40,000 to 60,000 live births.2 In the study, fenfluramine
More news about: UCB
Jun 27, 2025, 06:30 ET ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
/PRNewswire/ -- ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New
More news about: ProBio Inc.
Jun 26, 2025, 22:46 ET MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance biological and molecular understanding of various pathologies.
More news about: MGI TECH
Jun 26, 2025, 20:27 ET SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Jun 26, 2025, 20:05 ET Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
momentum, invest in our future, and continue delivering the high-quality tools and support our clients rely on to advance the next generation of cell and gene therapies." About SynthegoSynthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with
More news about: Synthego
Jun 26, 2025, 16:15 ET Origin Agritech Announced Financial Results for the Six Months Ended March 31, 2025
Henan, and developed a large-scale corn genetic platform for efficient functional gene exploration. Origin has accumulated nearly 300,000 corn germplasm resources and received authorization for multiple gene editing traits, including leaf angle, plant height, and rust resistance.Corporate
More news about: Origin Agritech Limited